$UBX Long-Term Target $18.90

NASDAQ:UBX   Unity Biotechnology, Inc.
Unity Biotechnology is a pharmaceutical company focused on creating a drug that will extend the years people can live unburdened by disease. This drug has shown a great deal of promise and is currently in phase two clinical trials. As the trials progress, we can expect the price to rise dramatically, and given the current uptrend, My forecast is $18.90 by May 2022. However, that could just be the beginning. This stock is not very popular yet, as it is very few hedge funds. This means that if phase two goes well, Unity Biotech could grow to ridiculous prices. We could be looking at the next AMGN or VRTX. This company is an extremely good investment. Like and follow for more biotech ideas :) Happy Trading!

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.